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Over the past decade, several investigators reported that a fraction of the RAF kinases are recruited to the mitochondria. Although we are still
far from a global understanding of the molecular consequences of RAF translocation on mitochondrial physiology and metabolism, the recent
description of some molecular interactions that are established by C-RAF in this organelle, principally with the proteins Bcl-2 and Bag-1, provides
some clues. Here, we discuss the possible contribution of RAF targeting to mitochondria to their modulation of apoptosis signaling, as well as to
this organelle's physiology. In addition, we discuss the possible modulation of the mitochondrial metabolism by RAF oncogenes in the context of
cancer.
© 2007 Published by Elsevier B.V.Keywords: RAF kinases; Mitochondria; Apoptosis; Bcl-2; MetabolismRaf kinases are important components of the cell signal
transduction machinery in mammalian cells. In normal and
cancer cells, a cascade of phosphorylations results from their
activation that relays various signals to promote cellular growth.
The plasma membrane is believed to be the place of activation
of the Extracellularly-Regulated Kinases (ERKs), their best-
characterized cellular target to date [1]. However, recent studies
show that RAF kinases, and particularly C-RAF, are addition-
ally present on mitochondria. Here, we attempt to summarize
the current knowledge regarding Raf kinases' interaction with
this organelle. We discuss: (i) the recruitment of RAF kinases to
mitochondria, (ii) their localization in this organelle and the
molecular interactions they establish, (iii) their regulation of the
mitochondrial contribution to programmed cell death, (iv) their
regulation of the cell metabolism, particularly during oncogenic
transformation.
1. RAF recruitment to mitochondria
Themitochondrial interaction properties of the kinase C-RAF
were first detected by Wang et al. [2]. These authors reported in
1996 that in human embryonic kidney 293 cells stably⁎ Corresponding author. Tel.: +49 931 201 45149; fax: +49 931 201 45835.
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doi:10.1016/j.bbamcr.2006.10.012overexpressing an activated version of C-RAF tagged with the
Green Fluorescent Protein (GFP), the introduction of Bcl-2
caused a redistribution of the fluorescence towards the
mitochondria [2]. These observations prompted other studies
that confirmed the localization of the kinase C-RAF at
mitochondria in cancer and normal tissues [3–10].
Consistent with the possibility that mitochondria could be
both regulators of RAF kinases and target organelles for them,
investigators have examined the mechanisms that could regulate
this targeting at both levels.
At the mitochondrial level, variations in the levels of the
proteins of the Bcl-2 family could play a regulatory role for the
recruitment of RAF. Following the early work of Wang et al. on
Bcl-2 overexpression-mediated recruitment of C-RAF to
mitochondria [2], other investigators reported the “mirror”
observation, that RNA interference directed against Bcl-2
reduces the mitochondrial localization of C-RAF in 293 cells
[9]. Bcl-2 might play a role directly, or through its ability to
interact with cofactors like the protein Bag-1 (Bcl-2-associated
Athanogene) [10]. Some adaptor proteins involved in signal
transduction such as Grb10 [11], the small GTPases of the Ras
family [12,13], and even possibly growth factor receptors with
tyrosine-kinase activity such as the EGFR (Epidermal Growth
Factor Receptor) [14] are present at mitochondria. These
proteins are upstream regulators of RAF kinases in the plasma
Table 1
A list of specific protein–protein interactions that RAF kinases might establish
at the mitochondria
RAF isoform Interaction partner: evidence Localization Reference
CRAF Bcl-2: Y2H, coIP, IVI MOM [2,19]
BRAF, CRAF Bag-1: Y2H, coIP, IVI MOM [10,17]
CRAF VDAC/Porin: coIP, IVI MOM [18]
ARAF hTOM/hPrp6a: Y2H MOM [19]
hTIM: Y2H MIM [19]
Y2H: yeast two hybrid, coIP: co-immunoprecipitation, IVI: in vitro interaction.
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mitochondrial level, although this possibility has not yet been
fully explored.
Besides these indications that mitochondria could recruit and
activate RAF kinases, the literature contains indications that
these organelles might also be targets for activated RAF kinases.
Recently, a striking example of regulated recruitment of C-RAF
to the mitochondria was obtained in an analysis of primary
endothelial cells exposed to basic Fibroblast Growth Factor
(bFGF) [7]. In this context, bFGF activates C-RAF mitochon-
drial translocation and promotes cell survival independently of
the canonical MEK-ERK pathway [7]. In this work, as well as in
a more recent report, a role for the kinase PAK1 (p21-activated
kinase) as a regulator for C-RAF mitochondrial interaction was
proposed, through phosphorylations of Ser-338 and -339 of C-
RAF [9]. However, this point remains controversial, because
these residues also control RAF kinase activation [15]. Whether
the phosphorylation of C-RAF on Ser-338 and -339 signals the
interaction of C-RAF with mitochondria, regulates the activity
of C-RAF, or even follows the recruitment of the kinase remains
to be determined.
RAF kinases interact with chaperones, particularly of the
Hsp90, Hsp70, and 14-3-3 family. This association constitutes
another aspect of RAF regulation that might be relevant to
mitochondrial interaction. Although this aspect has until now
not been directly investigated, chaperones indeed often
regulate the interaction of proteins with intracellular mem-
branes [16].
At this stage, we would like to formulate the following
comments regarding the literature on the interaction of RAF
with mitochondria
(i) Most of the data published concern C-RAF. This point is
of importance, considering that the RAF family consists
of three members: A-RAF, B-RAF and C-RAF, encoded
by distinct genes and characterized by divergent
sequences at their amino-terminus [1]. Because the
isoforms A-RAF and B-RAF exhibit generally low,
tissue-specific expression patterns that render difficult
the comparative study of their subcellular distribution,
almost nothing is known regarding their ability to interact
with mitochondria. C-RAF is the only isoform for which
mitochondrial targeting properties are a matter of
consensus.
(ii) While the literature offers an apparent consensus regard-
ing the pro-survival effect of this interaction [3–10],
virtually nothing is known on its regulation. Whether
mitochondria recruit RAF kinases to regulate them and/or
constitute targets are two non-exclusive possibilities that
should be investigated in specific cellular contexts.
(iii) Virtually nothing is known on the structural aspects of C-
RAF interaction with mitochondria in particular, and with
membrane organelles in general: what are the receptors?
Through which part of their structures do RAF kinases
interact with mitochondria? Do chaperones play a role in
the process? Probably, in vitro approaches relying on
purified components will be required in order to deter-mine how RAF kinases interact with mitochondria, and
how their affinity for this organelle is regulated.
2. Where are RAF kinases and what molecular interactions
do they establish at the mitochondrial level?
Mitochondria are organized into different compartments,
limited by two mitochondrial membranes, the mitochondrial
outer membrane (MOM) and the mitochondrial inner membrane
(MIM), and specialized in different aspects of the cell meta-
bolism. To understand the function of a protein that localizes to
mitochondria, it is essential to first know in which of these sub-
mitochondrial compartments this protein is located. In this
section, we discuss the observations that are relevant to RAF
sub-mitochondrial localization.
From the early work of Wang et al. [2], C-RAF was found to
be an active anti-apoptotic protein when it was targeted to the
MOM by means of a fusion with the transmembrane domain of
TOM70 (formerly known as Mas70p), a resident protein of this
membrane [2]. Similar observations were obtained by other
groups [3,4], therefore strongly suggesting that the MOM
constitutes an important site of action for C-RAF. This was later
supported by multiple reports describing molecular interactions
between C-RAF and other proteins located at the MOM,
through the combined use of yeast two hybrids screens, co-
immunoprecipitations, and assays measuring in vitro interac-
tions (Table 1, ref [2,9,10,17–19]). Currently, the main
interaction partners for C-RAF found at the MOM are the
anti-apoptotic protein Bcl-2 [2] and the protein Bag-1 [10,17]
(Fig. 1). We will discuss the relevance of these molecular
interactions in the next section, devoted to apoptosis regulation.
There is currently no information showing the relevance of the
other interactions listed in Table 1. Nevertheless, strong
evidence for the ability of C-RAF to signal from the MOM
emerged from these works.
Recently, some authors challenged the notion that RAF
kinases play a role exclusively at the MOM [19]. This new
possibility was introduced with the observation that one isoform
of the family of RAF kinases, A-RAF, is an intrinsic mito-
chondrial protein in rat liver mitochondria [19]: this conclusion
was reached through the combined use of electron microscopy
coupled with immunogold labeling and a protease-protection
assay. Furthermore, in a yeast two hybrid screen, Yuryev et al.
found that A-RAF could potentially interact with two pro-
teins, which these authors named hTIM and hTOM because
of their sequence homology with some components of the
Fig. 1. An overview of protein–protein interactions established by RAF
kinases in mitochondria. RAF kinases could interact with various proteins of
the MOM, among which VDAC, Bcl-2 and its associated factor Bag-1.
Active RAF kinases promote the phosphorylation of the pro-apoptotic protein
BAD on Ser residues, thereby favoring their association with cytoplasmic
chaperones of the 14-3-3 family. This event results in the extraction of BAD
from the mitochondrial membranes. In addition to their localization at the
level of the MOM, RAF kinases could eventually be located inside
mitochondria. The protein interactions that might be relevant to mitochondrial
import are labeled with question marks to signal the fact that they remain
putative (TOM and TIM stand for Translocase of the Outer Membrane, and
Translocase of the Inner Membrane).
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ospora crassa [19]. Since then however, no report confirmed
the validity of these observations in human or animal tissues
and cell lines sofar. Furthermore, hTOM was independently
identified as the human homologue of the splicing factor Prp6a,
and localized in the nucleus of eukaryotic cells [20,21], raising
doubts about its ability to function as a mitochondrial import
receptor. As a consequence, it remains unclear whether all or
some of the isoforms of RAF kinases are indeed intrinsic
mitochondrial proteins.
3. Mitochondrial targeting of RAF and Apoptosis
regulation
Mitochondria are a convergence point for a variety of stimuli
that induce apoptosis, a type of programmed cell death playing a
crucial role in the development and the maintenance of tissues
of multicellular organisms [22]. The disruption of the MOM
permeability barrier is an important step in apoptosis, because it
allows the release of proteins such as Cytochrome c that are
normally residing in the mitochondrial intermembrane space.
This process is regulated by the proteins of the Bcl-2 family,
although how the permeabilization exactly occurs is hotly
debated [22,23]. In their seminal work, Wang et al. showed that
the mitochondrial targeting of C-RAF confers pro-survival
properties to this molecule [2]. In addition, they found that the
protein BAD, a member of the family of Bcl-2 proteins, is
phosphorylated upon C-RAF recruitment to the mitochondria[2]. The knock out of C-RAF in mice later confirmed the anti-
apoptotic effects of C-RAF [24,25]. Although there are now
indications that C-RAF is endowed with pro-survival mechan-
isms through its ability to interact with cytoplasmic kinases like
ASK1 [26] and MST2 [27], the interaction of C-RAF with
mitochondria is probably an important component of its pro-
survival action. In this section, we want to discuss past and
ongoing works that address this possibility. In particular, we
propose to detail two aspects of these investigations: (i) is C-
RAF active as a kinase and how is it regulated on the surface of
mitochondria? (ii) Is BAD an important substrate of C-RAF,
and how does its phosphorylation affect apoptosis regulation?
Is RAF active as kinase and how is it regulated on the surface
of mitochondria? Experiments using overexpressed mitochond-
rially-targeted forms of C-RAF revealed that the kinase activity
of C-RAF is required for the mitochondrial prosurvival effects
[3,4]. At the level of the plasma membrane, C-RAF is active
within large multi-molecular protein complexes including
scaffolds like the protein KSR (Kinase Suppressor of Ras)
[28]. While this probably holds true for C-RAF recruited to
mitochondria, the informations that are currently available
regarding the composition of the complex are fragmentary,
except for one protein, Bag-1, that seems to play a specific role
at this level [10]. Bag-1 is the main representative of a family of
proteins characterized by the presence of a domain of ap-
proximately 70 amino acids, the BAG domain. Bag-1 is a multi-
functional protein, whose main biochemical role, conferred by
the BAG domain, is probably to regulate negatively the activity
of the chaperone Hsp70 by promoting the release of its
substrates. In parallel, Bag-1 is a pro-survival factor that
interacts with Bcl-2 as well as with C-RAF [17]. Gotz et al.
recently reported the knock-out of the gene BAG-1 in mice [10].
Strikingly, these mice exhibit massive levels of apoptosis in the
haematopoietic and neuronal lineages. Apoptosis observed in
these cells is associated with a reduced recruitment of the RAF
kinases to mitochondria, and a defective phosphorylation of
BAD [10]. These results illustrate the fact that specific
mechanisms regulate RAF kinases at the mitochondria, and
suggest that Bag-1 is a regulator of RAF at this level. However,
how this protein exactly works remains a point of discussion: a
direct interaction between Bag-1 and C-RAF could stimulate
the kinase activity [17,29]. Alternatively, Bag-1 effects could be
attributable to its activity as co-chaperone of the Hsp70 family:
according to this last scenario, Bag-1 would influence the
mitochondrial activity of C-RAF by controlling its interaction
with chaperones.
Is BAD an important substrate of C-RAF, and how does its
phosphorylation affect apoptosis regulation? BAD belongs to
the “BH3-only” subset of the Bcl-2 family of proteins. Like the
other proteins that belong to this subset, BAD probably plays a
role as sentinel, being able to perceive variations in the normal
cellular homeostasis. A widely accepted model is that BAD is
part of the machinery that perceives the presence of trophic
factors in the cell medium [30]. Upon addition of protein growth
factors and the activation of RAF kinases, BAD is phosphory-
lated on Serine residues (on the positions 112, 136 and 155 of
murine BAD, or their equivalent residues 75, 99 and 118 in the
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is probably critical for the pro-survival effects of growth
factors [30], there are few studies that address conclusively
the mechanisms and the consequences of each of these
phosphorylations.
Although the RAF pathway certainly contributes in vivo to
BAD phosphorylation [30], the nature of the kinase(s) that
directly phosphorylate(s) BAD is a matter of controversy. Other
kinases than the RAFs, principally protein kinase A (PKA) and
the protein kinase Akt/PKB, can phosphorylate BAD directly:
indeed, both proteins form protein complexes with BAD
[10,32], and the major phosphorylation sites of BAD are
preferred target residues for them [33]. RAF could either
directly phosphorylate BAD, promote indirectly its phosphory-
lation by PKA or PKB, or maybe even recruit a small but
functionally important pool of MEK. At this point, one should
mention that the existence of multiple interplays between the
different kinase pathways renders the analysis of their
individual contribution extremely difficult. More studies
examining the ability of RAF kinases to operate directly as a
“BAD kinase” in vivo are clearly warranted.
Paradoxically, there are more informations regarding the
consequences of BAD phosphorylation. Following its phos-
phorylation on Ser 112 and 136, BAD interacts with the
chaperones of the 14-3-3 family, and this association removes
BAD from the mitochondrial membranes [31]. The residue
Ser155, on the other hand, is located in the BH3 domain of
BAD, and its phosphorylation probably interferes with BAD's
ability to interact with other members of the Bcl-2 family.
Recently, we reported a possible additional regulatory para-
meter for BAD: its interaction with non-mitochondrial,
cholesterol-enriched membranes [34] (Fig. 2). Taken together,Fig. 2. BAD colocalizes with non-mitochondrial, cholesterol-enriched membranes. H
dominant positive version of the kinase Akt/PKB to maintain their viability. Simultane
and cholesterol-enriched membranes were stained with filipin (B). In these pro-surviv
enriched membranes (D), but not with mitochondria (E).phosphorylations regulate BAD at multiple levels, ranging from
subcellular localization to modulation of the spectrum of its
molecular interactions.
Clearly, we do not know if BAD phosphorylation accounts
for the totality of mitochondrial RAF anti-apoptotic effects, and
we do not have yet a molecular understanding of C-RAF
interference with mitochondrial participation to apoptosis.
Fundamental studies on mitochondria should give important
clues in this respect, especially considering that many new
facets of the regulation of this organelle are being unraveled.
Among them are the regulation of the mitochondrial network
morphology, and the organization of mitochondrial internal
membranes [35]. In the next section, we would like to discuss
the possibility that some of the roles of RAF kinases might also
stem from their ability to control another interesting new aspect,
mitochondrial contribution to the cell metabolism.
4. A role for mitochondrial RAF kinases beyond death
regulation?
Mounting evidence indicate the metabolism does not pas-
sively adapt to the cell signaling, but that, instead, it plays a
decisive role in cell fate. This notion is important in oncology,
because, in certain situations, oncogenes target metabolic
pathways to induce transformation [36]. Before we discuss
how this regulation might apply to mitochondria and be relevant
to RAF oncogenes, we would like to review briefly how this
organelle takes part in the cellular metabolism.
In most of the normal eukaryotic cells, mitochondria play a
crucial role in cellular energetics (Fig. 3). Mitochondria host
most of the metabolic reactions that are involved in coupling the
oxidation of sugars and lipids with the generation of ATP,eLa cells grown on glass coverslips were transfected with GFP-BAD (A) and a
ous labeling of mitochondria was ensured by co-transfection of DsRED-mito (C)
al conditions, we found that BAD colocalizes to a large extent with cholesterol-
Fig. 3. Mitochondrial involvement in cell metabolism. Mitochondria host in their matrix the enzymes of the tricarboxylic-acid (TCA) cycle, also known as Krebs cycle.
The enzymatic reactions that constitute this cycle convert pyruvate, the final nutrient produced by glycolysis and the β-oxidation of fatty acids, into reduced NADH
(Nicotinamide–Adenine–Dinucleotide) and FADH (Flavin–Adenine–Dinucleotide). Oxidative phosphorylation (OXPHOS) is catalyzed by the respiratory chain,
which extracts the high-energy electrons from NADH and FADH, and transfer them to the final acceptor, oxygen. Besides their contribution to the energy metabolism,
mitochondria play a key role in various metabolic reactions: here, we illustrate some of those that seem to play a role in cancer cells, like the biosynthesis of glutamine,
lipogenesis (blue boxes). Mitochondria are also able to induce the activation of specific signal transduction pathways, for example through the production of ROS or
through the activation of transcription factors like HIF1α (red).
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chondria also play other crucial roles that become more and
more underlined nowadays, such as their regulation of the cell
signal transduction or their contribution to various anabolic
reactions [37]. In many cell types, the respiratory chain
constitutes the primary source of reactive oxygen species
(ROS) and oxidant species. Although these oxidants are
traditionally perceived as toxic molecules, there are indications
that they also serve a physiologic signaling purpose [38,39].
Mitochondria also play a role in the regulation of the Ca2+
signal, through their ability to store and release this ion in a
regulated fashion [40]. Collectively, mitochondria are emerging
as signaling organelles: specific transduction pathways are put
in motion upon variations imposed on the mitochondrial
intermediary metabolism, the production of ROS, or the
ΔΦm. For more information on this vast topic, we refer the
reader to an excellent review [41].
Mitochondria are also an important place for various
anabolisms. The intermediates of the TCA cycle can for
example be synthesized for non-energetic purposes (a process
called anaplerosis) and exported to the cell cytoplasm [42].
Citrate is used for lipid synthesis after its mitochondrial export.
The key enzyme in this process is ATP citrate lyase, which
catalyzes the conversion of citrate into cytosolic acetyl-CoA
[43,44]. Another intermediate, α-ketoglutarate, can be trans-
formed into glutamate and therefore can be used as nitrogen
supply for biosynthetic reactions. Interestingly, there are tight
connections between the energetics/anabolic/signaling roles of
mitochondria: some of the TCAmetabolites, are now considered
to play a role as “second messengers” in the cytoplasm, such as
α-ketoglutarate and succinate [45].Tumors commonly exhibit a profound modification of their
energy metabolism that is commonly called the “Warburg
effect”. This modification consists in an increased tendency to
use glycolysis for energy supply, instead of oxidative
phosphorylation, and is found in approximately two thirds of
tumors [45,46]. The source of this deficient contribution of
mitochondria to cellular energetics is unclear. In molecular
terms, there are as yet no mitochondrial aberrations which
appear to be common to all cancer cells, although the protein
profile and the activities of some mitochondrial proteins are
often found altered [47]. One likely explanation might be that
cancer cells privilege certain aspects of the mitochondrial
metabolism, like for example lipid and nitrogen anabolism. But
some recent experimental results indicate that the contribution
of mitochondria is likely to go beyond a strict metabolic
adaptation. Rather, alterations in mitochondrial metabolism
could actively promote cell transformation and tumor progres-
sion ([48,49],reviewed in ref. [45]). Besides the control of the
apoptotic machinery, the cellular redox state and the release of
metabolites of the TCA cycle are important components in the
oncogenic effects of these mitochondrial alterations. The
mitochondrial redox metabolism of tumor cells can directly
influence the cell cycle [50], as well as tumor angiogenesis [51].
The TCA cycle can also directly influence tumor progression,
through the ability of its metabolites to regulate transcription
factors like HIF-1α (Hypoxia-Induced Factor-1α) [49].
We know little regarding the metabolic alterations that could
be induced by RAF kinases once they are recruited to the
mitochondria. However, there are some indications that RAF
kinases can induce some of the metabolic features that are
present in cancer cells, and principally the Warburg effect: in
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version of C-RAF is sufficient to increase the cellular content of
glycolytic metabolites [52]. Even if it remains to be documented
whether the mitochondrial targeting of RAF plays a role, there
again, the protein BAD, being a substrate for mitochondrial
RAF kinases constitutes a possible candidate for a regulatory
effect of RAF: in hepatocytes, BAD is part of a protein complex
that includes the enzyme glucokinase and catalyzes the first step
of glycolysis [32]. In the absence of BAD, hepatocytes exhibit a
reduced glucokinase activity, and, consequently, they respire
less in the presence of glucose [32].
The literature does not contain, to the best of our knowledge,
any direct description of the effects of RAF kinases on
mitochondrial metabolism, but only reports based on the
introduction of RAS oncogenes. Because Ras small GTPases
have effectors other than RAFs, it is still unclear to which extent
the RAF kinases might account for these effects: in a human
fibroblast cell line in which an activated version of Ras is
introduced, Ramanathan et al. reported a reduction in the level
of all metabolites of the TCA cycle (citrate, malate and
fumarate) [53]. Also in primary human fibroblasts, Ras
stimulates the mitochondrial production of ROS [50], possibly
through a modulation of the coupling of respiratory complexes
[54].
Because there are yet no indications that the mitochondrial
recruitment of RAF can induce any of these events, any
discussion remains speculative. An important work remains to
be done in order to determine the effects of RAF kinases on
mitochondrial metabolism. The study of RAF kinases offers the
opportunity to analyze mitochondrial physiology in the context
of transformation. Clearly, it will be interesting to analyze the
effects of Raf kinases on mitochondrial physiology and
metabolism in the different animal models where there are
indications that mitochondrial-targeting of C-RAF might play
an oncogenic role [3,55]. In line with this interesting possibility,
reversible phosphorylation is emerging as a frequent regulation
mode inside mitochondria: many kinases and phosphatases are
now described that are either resident, or recruited to all
compartments of this organelle [56].
5. Conclusion
Approximately 10 years after the first observation that RAF
interact with mitochondria, we still know very little on the
regulation and the targets for these kinases at this level.
Although most of the previous work focused on their anti-
apoptotic effects, RAF kinases could influence important
aspects of the cell life through mitochondrial targeting. With
the field of mitochondrial research expanding at a fast pace,
many possible new aspects of regulation are coming to light:
mitochondrial biogenesis, morphology and contribution to cell
regulation and signaling, making mitochondria strikingly
dynamic organelles [57]. Future studies should aim at
determining whether these aspects of physiology are under
the regulation of RAF kinases. These studies will further our
knowledge on RAF kinases by identifying new regulations and
new targets for them. In addition, they might implicate thesekinases in yet poorly understood processes, like ageing for
example, in which the mitochondria might play an important
role [58].
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